<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661683</url>
  </required_header>
  <id_info>
    <org_study_id>20-001570</org_study_id>
    <nct_id>NCT04661683</nct_id>
  </id_info>
  <brief_title>Secondhand Effects of E-Hookah Aerosol</brief_title>
  <official_title>Investigating Secondhand Effects of E-Hookah Aerosol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the United States, exposure to secondhand smoke accounts for greater than 35,000 deaths&#xD;
      annually from cardiovascular disease in never-smokers. Electronic (e-) hookahs are a new&#xD;
      category of vaping devices gaining popularity among youth. While more is known on the acute&#xD;
      effects of active hookah smoking and the literature is emerging on active e-hookah vaping,&#xD;
      virtually nothing is known about the acute cardiovascular effects of secondhand exposure to&#xD;
      e-hookah aerosol. The study aims to examine the acute effects of secondhand exposure of&#xD;
      e-hookah aerosol on endothelial and vascular function. Eligible volunteers will be invited to&#xD;
      participate in a total of 2 study visits (2-4 hours each): exposure to e-hookah aerosol&#xD;
      delivered by a hookah smoking/vaping machine, and for comparison, before and after clean air.&#xD;
      Non-invasive blood pressure and blood flow measurements will be taken before and after the&#xD;
      exposure sessions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>30 minutes</time_frame>
    <description>Change in Flow-Mediated Dilation, percent change pre to post exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>30 minutes</time_frame>
    <description>change in pulse wave velocity, m/s-1 pre to post exposure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hookah Smoking</condition>
  <condition>Secondhand Aerosol</condition>
  <condition>Vascular Stiffness</condition>
  <condition>Vaping</condition>
  <arm_group>
    <arm_group_label>Peripheral Endothelial Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brachial artery flow-mediated dilation will be used to measure endothelial function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central Arterial Stiffness</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulse wave velocity will be used to measure arterial stiffness.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>e-hookah aerosol</intervention_name>
    <description>Exposure to secondhand aerosol delivered by an e-hookah vaping machine for 30 mins</description>
    <arm_group_label>Central Arterial Stiffness</arm_group_label>
    <arm_group_label>Peripheral Endothelial Function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clean air</intervention_name>
    <description>Exposure to clean air for 30 mins.</description>
    <arm_group_label>Central Arterial Stiffness</arm_group_label>
    <arm_group_label>Peripheral Endothelial Function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  21-35 years old&#xD;
&#xD;
          -  Never a smoker: do not use any tobacco products or nicotine delivery systems,&#xD;
             including cigarettes, cigars (traditional and filtered), cigarillos, hookah, smokeless&#xD;
             tobacco (i.e., loose snus, moist snuff, dip, spit, or chewing tobacco), pipe tobacco,&#xD;
             snus pouches, dissolvable tobacco or vaping.&#xD;
&#xD;
          -  no evidence of cardiopulmonary disease by history/physical&#xD;
&#xD;
          -  blood pressure (BP) &lt; 140/90 mmHg&#xD;
&#xD;
          -  resting heart rate (HR) &lt; 100 bpm&#xD;
&#xD;
          -  BMI &gt;18 or &lt; 30kgâ€¢m2&#xD;
&#xD;
          -  no prescription medication&#xD;
&#xD;
          -  No exposure to environmental tobacco smoke for at least one week prior to the study&#xD;
             date.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  exhaled carbon monoxide &gt;6 ppm&#xD;
&#xD;
          -  (+) pregnancy test&#xD;
&#xD;
          -  other conditions deemed unsafe to participate, such as breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary Rezk-Hanna, PhD</last_name>
    <phone>310-206-8654</phone>
    <email>MRHanna@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-8361</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byron Bustos, B.S</last_name>
      <phone>310-562-4348</phone>
      <email>BBustos@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joye Cheng, B.S</last_name>
      <phone>310-562-4348</phone>
      <email>Chiao-weicheng@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Mary Rezk-Hanna, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

